Merck KGaA (FRA:MRK) has been assigned a €119.00 ($141.67) price objective by equities researchers at Kepler Capital Markets in a note issued to investors on Thursday. The firm currently has a “buy” rating on the healthcare company’s stock.

Several other equities research analysts also recently commented on MRK. Morgan Stanley set a €103.00 ($122.62) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Monday, May 29th. Warburg Research set a €116.00 ($138.10) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Monday, May 29th. DZ Bank AG reissued a “neutral” rating on shares of Merck KGaA in a research report on Monday, May 29th. Berenberg Bank set a €106.00 ($126.19) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Monday, May 29th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Merck KGaA in a research report on Wednesday, June 7th. Thirteen equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of €108.38 ($129.02).

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/21/merck-kgaa-mrk-given-a-119-00-price-target-at-kepler-capital-markets.html.

Merck KGaA Company Profile

.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.